Freedom Investment Management Inc. Purchases Shares of 12,870 Hims & Hers Health, Inc. $HIMS

Freedom Investment Management Inc. purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 12,870 shares of the company’s stock, valued at approximately $380,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Farallon Capital Management LLC raised its stake in shares of Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the period. Northern Trust Corp increased its position in shares of Hims & Hers Health by 19.5% in the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after acquiring an additional 397,310 shares during the last quarter. Yong Rong HK Asset Management Ltd increased its position in shares of Hims & Hers Health by 41.2% in the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after acquiring an additional 700,100 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Hims & Hers Health in the first quarter valued at about $58,403,000. Finally, Two Sigma Investments LP increased its position in shares of Hims & Hers Health by 37.9% in the fourth quarter. Two Sigma Investments LP now owns 1,967,354 shares of the company’s stock valued at $47,571,000 after acquiring an additional 540,274 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,571 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $44.53, for a total transaction of $114,486.63. Following the completion of the sale, the insider owned 150,450 shares in the company, valued at $6,699,538.50. The trade was a 1.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Michael Chi sold 2,100 shares of the business’s stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $57.52, for a total value of $120,792.00. Following the sale, the insider owned 278,654 shares of the company’s stock, valued at approximately $16,028,178.08. This represents a 0.75% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,383,847 shares of company stock worth $71,247,924. Insiders own 13.71% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of recent research reports. Zacks Research downgraded Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Wall Street Zen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Piper Sandler reaffirmed a “neutral” rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Finally, Truist Financial lowered their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research report on Monday, August 18th. Two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Reduce” and an average price target of $38.92.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $44.07 on Thursday. The business’s 50 day moving average price is $50.76 and its two-hundred day moving average price is $45.84. The company has a market cap of $9.96 billion, a PE ratio of 55.09, a price-to-earnings-growth ratio of 3.06 and a beta of 2.08. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.Hims & Hers Health’s quarterly revenue was up 72.6% compared to the same quarter last year. During the same period last year, the firm earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.